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Abstract
Objective: Plasma osteoprotegerin (P-OPG) is an independent predictor of cardiovascular disease in diabetic and
other populations. OPG is a bone-related glycopeptide produced by vascular smooth muscle cells and increased P-
OPG may reflect arterial damage. We investigated the correlation between P-OPG and coronary artery disease
(CAD) in asymptomatic type 2 diabetic patients with microalbuminuria.
Methods: P-OPG was measured in 200 asymptomatic diabetic patients without known cardiac disease. Patients
with P-NT-proBNP >45.2 ng/l and/or coronary calcium score (CCS) ≥400 were stratified as high risk of CAD (n =
133), and all other patients as low risk patients (n = 67). High risk patients were examined by myocardial perfusion
imaging (MPI; n = 109), and/or CT-angiography (n = 20), and/or coronary angiography (CAG; n = 86). Significant
CAD was defined by presence of significant myocardial perfusion defects at MPI and/or >70% coronary artery
stenosis at CAG.
Results: Significant CAD was demonstrated in 70 of the high risk patients and of these 23 patients had >70%
coronary artery stenosis at CAG. Among high risk patients, increased P-OPG was an independent predictor of
significant CAD (adjusted odds ratio [CI] 3.11 [1.01-19.54] and 3.03 [1.00-9.18] for second and third tertile vs.first
tertile P-OPG, respectively) and remained so after adjustments for NT-proBNP and CCS. High P-OPG was also
associated with presence of >70% coronary artery stenosis(adjusted odds ratio 14.20 [1.35-148.92] for third vs. first
tertile P-OPG), and 91% of patients with low (first tertile) P-OPG did not have >70% coronary artery stenosis.
Conclusions: Elevated P-OPG is an independent predictor of the presence of CAD in asymptomatic type 2 diabetic
patients with microalbuminuria.
Introduction
Coronary artery disease (CAD) is the most important
determinant of the excessive morbidity and mortality in
type 2 diabetic patients, especially in patients with albu-
minuria[1]. Plasma osteoprotegerin (P-OPG) is a pro-
mising predictor of cardiovascular disease (CVD) in
high risk diabetic populations, as well as in other popu-
lations [2-5]. Osteoprotegerin is a member of the tumor
necrosis factor (TNF) receptor superfamily acting as a
soluble decoy receptor for the receptor activator of
nuclear factor-b ligand (RANKL) and TNF-related
apoptosis-inducing ligand (TRAIL) preventing osteoclast
activation and bone resorption, and participating in
immune regulation and cell survival [6,7]. OPG mRNA
has been detected in a variety of human tissues, includ-
ing the lung, heart, and kidney[6]. Indeed, OPG is pre-
sent in the arterial wall and increased P-OPG has been
suggested to reflect the increased OPG content in ather-
osclerotic arterial tissues[8]. OPG is up-regulated in cal-
cified coronary plaques and is associated with coronary
angiographic disease severity and cardiovascular events
independent of conventional risk factors [9,10]. Patients
with diabetes have elevated P-OPG [11] and in uncom-
plicated type 2 diabetic patients that were followed for
18 months, P-OPG predicted cardiovascular events but
was also associated with subclinical coronary calcifica-
tion burden, as measured by non-invasive CT-deter-
mined coronary calcium score (CCS)[4]. We have
recently shown that OPG is a strong and independent
predictor of cardiovascular (CVD) morbidity and
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mortality in type 2 diabetic patients in a study with 17
years of follow-up[3]. The underlying causes of CVD in
patients with elevated P-OPG levels are not known and
the putative role of asymptomatic CAD in this regard is
not clear. Consequently, we evaluated if P-OPG could
serve as a biomarker for subclinical CAD in asympto-
matic type 2 diabetic patients with microalbuminuria.
Methods
Patient cohort and investigations
In a cross-sectional study at Steno Diabetes Center, we
identified from January 2007 to February 2008 a conse-
cutive cohort of 200 type 2 diabetic patients with
microalbuminuria but without prior heart disease and
with normal P-creatinine. All patients received inten-
sive multifactorial intervention aimed at improved glu-
cose, lipid, and blood pressure control, as well as
antithrombotic therapy and lifestyle modification
according to international treatment guidelines[12].
The design and a selection of clinical measurements of
the study have previously been described[13]. In brief,
P-NT-proBNP was analysed by an established immu-
noassay[14]. Tests for autonomic neuropathy, heart
rate variability assessed by the expiration-inspiration
variation of the heart rate and somatic nerve function
(vibratory perception threshold) evaluated by biothe-
siometry, were performed as reported previously[13].
Carotid artery intima media thickness (CIMT) was
measured at the posterior wall of the common carotid
artery 20 mm proximal to the bifurcation bilaterally
(Siemens Acuson Cypress ultrasound scanner) and cal-
culated as the mean of CIMT on both sides. Further-
more, systolic blood pressures in the ankle and big toe
were measured on both legs by strain gauge technique
and the lowest ankle and big toe pressures were
recorded and calculated as ankle-brachial (ABI) and
toe-brachial (TBI) blood pressure index[15]. Agaston
CCS was measured during a single breath hold using a
16 multidetector-row CT scanner with 3 mm slice
thickness (Philips Precedence MX 8000 IDT 16 slice,
Philips Medical Systems, Best, The Netherlands)[16].
Risk stratification scheme and assessment of CAD
CCS ≥400 was used to designate high risk diabetic
patients as recently reported [17]. Patients were strati-
fied into high risk and low risk groups based on elevated
P-NT-proBNP and elevated CCS as follows: 1) P-NT-
proBNP >45.2 ng/l or CCS ≥400 = high risk patients (n
= 133); the P-NT-proBNP cut-off was the median value
among the first 50 patients examined in the study and
this cut-off was in agreement with our earlier findings
[14], 2) P-NT-proBNP ≤45.2 ng/l and CCS <400 = low
risk patients (n = 67). High risk patients were examined
according to the following algorithm: 1) Patients with P-
NT-proBNP >45.2 ng/l underwent myocardial perfusion
imaging (MPI). Patients with abnormal MPI (n = 55) or
CCS >100 (n = 29) were referred for coronary angiogra-
phy (CAG); 2) Patients with P-NT-proBNP ≤45.2 ng/l
and CCS 400-1000 underwent CT angiography (CTA)
(n = 20; CTA was only used in patients with CCS 400-
1000 since severe coronary artery calcifications (CCS >
1000) compromise the validity of CTA)[18]. Patients
with abnormal CTA were referred for CAG (n = 15);
and 3) Patients with P-NT-proBNP ≤45.2 ng/l and CCS
>1000 underwent MPI (n = 9). Patients with abnormal
MPI (n = 6) were referred for CAG.
Significant CAD was defined as the presence of signifi-
cant myocardial perfusion defects on MPI, and/or >70%
stenosis of one or more major epicardial coronary
arteries at CAG as determined by quantitative analysis
(Phillips Medical Systems). The correlations between P-
NT-proBNP, CTA, MPI and CAG have been reported
previously[13].
Measurement of P-OPG
Blood samples for determination of OPG were collected
in EDTA-citrated tubes, centrifuged and the isolated
plasma was stored at -80°C until analysis within two
years from sampling. P-OPG was measured in random
order by a sandwich ELISA assay using commercially
available antibodies (R&D Systems, Minneapolis, MN,
USA), as previously described[19]. Briefly, mouse anti-
human OPG was used as capture antibody and a bioti-
nylated goat anti-human OPG for detection.
Recombinant human OPG was used for calibration and
the analytical range of the assay was 62.5-4.000 pg/ml.
The intra-assay coefficient of variation was 3% and the
inter-assay variation less than 8% in duplicate measure-
ments as previously reported[2].
The study was approved by the local ethics committee
and all patients gave written informed consent.
Statistical analyses
We investigated the associations of P-OPG with age, sex
and risk factors in both univariate and multivariate lin-
ear regression analyses. Risk factors included in the ana-
lyses were diabetes duration, HbA1c levels, systolic blood
pressure, P-total cholesterol, P-creatinine, heart rate var-
iation, vibration threshold, presence of retinopathy, level
of microalbuminuria, P-NT-proBNP, peripheral systolic
blood pressure in the toe, CIMT and CCS. Furthermore,
all patients were divided into groups of patients with or
without significant CAD as determined by MPI and/or
CAG. In most of our analyses, we included all patients
and thereby assumed that low risk patients (P-NT-
proBNP ≤45.2 ng/l and CCS <400, see above) were
without significant CAD. We did, however, also examine
if OPG was predictive of CAD within the high risk
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group alone, where all patients were investigated for
CAD by CTA, MPI and/or CAG. Comparisons between
groups were performed by an unpaired Student’s t-test
or the Pearson Chi-square test as appropriate. Data
were expressed as means and standard deviation (SD),
except for non-normally distributed variables, which
were log10-transformed before analysis and are reported
as medians (interquartile [IQ] range). As CCS was
highly skewed with values of zero, log10 (CCS + 1) was
used for analysis. Finally, the associations between sig-
nificant CAD and high, intermediate and low P-OPG
divided in tertiles or natural log-transformed P-OPG,
respectively, were assessed by multivariate logistic
regression models and expressed as odds ratios (ORs).
Covariate adjustments were made for age, sex and vari-
ables associated with significant CAD in the univariate
analysis (p < 0.05), including P-total cholesterol, P-
creatinine, peripheral systolic blood pressure, vibratory
perception threshold and heart rate variability unless
otherwise stated. In addition, the predictive accuracy of
the covariate-adjusted models with and without inclu-
sion of P-OPG were compared by generating receiver
operating characteristic (ROC) curves for endpoints and
the areas under the ROC curves (AUCs) were calcu-
lated. All data were analyzed by using statistical package
for social sciences (SPSS) version 14 for windows, and a
p-value less than 0.05 was considered as statistically
significant.
Results
Clinical characteristics
The clinical characteristics of all patients, low vs. high
risk patients, and patients with or without significant
CAD, respectively, are summarized in Table 1.
Table 1 The clinical characteristics of all patients, low vs. high risk patients and patients with significant coronary
artery disease (CAD; abnormal MPI and/or stenosis on coronary angiography)
All
patients
(n = 200)
Low-risk
patients
(n = 67)
High-risk
patients
(n = 133)
p-
values1
Patients without
sign. CAD
(n = 63)
Patients with
sign. CAD
(n = 70)
p-
values2
Sex no. (male%) 152 (76) 50(75) 102 (77) 0.747 14 (20) 56 (80) 0.33
Age (years) 59 (9) 53 (10) 61 (6) 0.001 57 (9) 62 (6) 0.001
Duration of diabetes (years) 13 (7) 10 (7) 14 (7) 0.001 12 (7) 15 (7) 0.006
BMI (kg/m2) 32.6 (5.8) 32.9 (6.0) 32.4 (5.7) 0.592 32.3 (5.8) 33.1 (5.7) 0.32
HbA1c (%) 7.9 (1.3) 8.0 (1.3) 7.8 (1.4) 0.194 7.8 (1.3) 7.8 (1.5) 0.80
Urinary albumin excretion rate (mg/24h)* 103
(39 - 230)
105
(44 - 194)
97 (38 - 97) 0.814 97 (43 - 194) 133 (38 - 491) 0.22
P-creatinine (μmol/l) 76 (18) 72 (17) 79 (19) 0.007 73 (17) 82 (20) 0.001
Systolic blood pressure (mmHg) 130 (17) 130 (16) 130 (18) 0.953 129 (17) 132 (18) 0.38
Total cholesterol (mmol/l) 3.9 (0.9) 4.1 (1.0) 3.8 (0.9) 0.041 4.0 (1.0) 3.8 (0.9) 0.08
Vibratory perception threshold mV -
mean of both sides
33 (15) 28 (14) 36 (14) 0.001 30 (14) 39 (13) 0.001
Heart rate variation during deep
breathing (bpm)*
7 (4.5-11.5) 9 (7-14) 6 (4-10) 0.001 8 (5-12) 6 (4-10) 0.013
Retinopathy no. (%) 120 (60) 28 (42) 92 (69) 0.001 71(55) 49 (70) 0.034
Oral antidiabetic medication no. (%) 170 (85) 57 (85) 113 (85) 0.98 111(85) 59 (84) 0.83
Insulin treatment no. (%) 124 (62) 38 (57) 86 (65) 0.28 77(59) 47 (67) 0.27
RAAS blockade no. (%) 196 (98) 65 (97) 131 (98) 0.48 127 (98) 69 (99) 0.67
Statin therapy no. (%) 189 (95) 62 (93) 127 (95) 0.39 122 (94) 67 (96) 0.58
Aspirin therapy no. (%) 183 (92) 58 (87) 125 (94) 0.076 119 (92) 69 (99) 0.98
Beta-blocker therapy no. (%) 27 (14) 2 (3) 25 (19) 0.002 12 (9) 15 (21) 0.016
Calcium channel blockers no. (%) 80 (40) 21 (31) 59 (44) 0.076 47 (36) 33 (47) 0.13
Use of diuretics no. (%) 128 (64) 35 (52) 93 (70) 0.014 82(63) 46(66) 0.71
Current smoker no. (%) 59 (30) 18 (27) 41 (31) 0.56 36(28) 23 (33) 0.45
NT-proBNP (ng/l) * 48.7
(18.6 - 95.0)
15.3 (9.3-26.3) 77.1
(48.7 - 141.7)
nr 30.1 (13.4 - 77.1) 76.7 (52.8 - 139.5) 0.001
Coronary Calcium Score* 183 (6-604) 7 (0-104) 417 (80-963) nr 71 (1-272) 748 (177-1518) 0.001
Data are expressed as means (SD) or * medians (interquartile range).
high-risk patients = patients with plasma NT-proBNP levels >45.2 ng/l or plasma NT-proBNP levels ≤45.2 ng/l and CCS ≥400, all other low-risk patients.
nr = not relevant.
p-values reflect comparison 1) between high- and low risk patients and 2) patients with or without significant CAD.
Reinhard et al. Cardiovascular Diabetology 2011, 10:70
http://www.cardiab.com/content/10/1/70
Page 3 of 7
P-OPG and established cardiovascular risk factors
Among the 200 type 2 diabetic patients, median (IQ
range) P-OPG was 1962 (1589-2409) pg/ml. P-OPG was
positively associated with age (r = 0.26, p < 0.001), dia-
betes duration (r = 0.18, p = 0.010), vibration threshold
(r = 0.24, p < 0.001), and P-NT-proBNP (r = 0.27, p <
0.001), while inversely related to increased heart rate
variation (r = -0.20, p = 0.007). P-OPG differed in
patients with or without retinopathy (2248 pg/ml vs.
1886, p = 0.002), but not between men and women (p =
0.12). P-OPG was not associated with HbA1c levels (p =
0.17), systolic blood pressure (p = 0.52), P-total choles-
terol (p = 0.21), P-creatinine (p = 0.43), microalbumi-
nuria (p = 0.11), peripheral systolic blood pressure in
the toe (p = 0.11), or CIMT (p = 0.36), respectively.
Interestingly, however, P-OPG was associated with CCS
(r = 0.24, p = 0.001). Adjusted OR of CCS ≥400 in
patients with P-OPG in the upper vs. lower tertile was
2.38 (0.996-5.69), p = 0.051 (Table 2). In addition, when
adding other CCS-associated variables (diabetes dura-
tion, vibration threshold, retinopathy and systolic blood
pressure in the big toe), high (third tertile) P-OPG levels
remained an independent predictor of CCS ≥400 with
OR 2.54 (1.01-6.37), p = 0.048.
Patients were also divided according to P-OPG tertiles
(<1679, 1679-2199, and >2199 pg/ml, respectively). The
patients with high (third tertile) P-OPG levels were
older (p < 0.001), had a longer diabetes duration (p =
0.006), more retinopathy (p = 0.003) and higher P-NT-
proBNP (p = 0.01). Furthermore, these patients had
higher vibration threshold (p < 0.001) and lower heart
rate variation (p = 0.024).
P-OPG and subclinical coronary artery disease
In 70 of 133 (53%) high risk patients, significant CAD
was demonstrated by MPI and/or CAG, corresponding
to 35% (70/200) of the total cohort. In addition, among
patients with significant CAD, 23 patients had signifi-
cant (>70%) coronary artery stenosis as defined by CAG.
In the looking of the whole cohort, P-OPG was higher in
patients with significant CAD (Figure 1). Furthermore, in a
logistic regression model, intermediate and high (second
and third tertile values) P-OPG compared to low (first ter-
tile values) were strongly associated with significant CAD
(Table 3). In addition, when adding P-NT-proBNP and
CCS to the adjusted model, second and third tertile P-
OPG concentrations remained independently predictive of
significant CAD with OR of 3.63 (1.24-10.60) and 3.95
(1.36-11.52), respectively. This pattern was also found
after exclusion of the low risk patients that did not
undergo cardiac examination by CTA, MPI and/or CAG,
i.e., OR 3.11 (1.01-19.54) and 3.03 (1.00-9.18), respectively.
In addition, the AUC in a ROC model predicting signifi-
cant CAD changed from 84% to 87% when adding P-OPG
tertiles to the covariate predictive model that included P-
NT-proBNP and CCS. Natural log-transformed P-OPG
was also predictive for significant CAD (adjusted OR 3.08
[1.05-9.08], p = 0.041). Finally, the number of patients
with >70% coronary artery stenosis were 2, 8 and 13 in the
first, second and third P-OPG tertiles, respectively, and for
Table 2 The relations between plasma OPG and the
prevalence of coronary atherosclerosis as defined by CCS
≥400
Parameter OR 95% CI p-value
Study population as a whole (n = 200) Coronary atherosclerosis
Unadjusted OPG (2rd tertile vs. 1st) 2.39 1.09-5.25 0.03
Unadjusted OPG (3rd tertile vs. 1st) 3.36 1.54-7.34 0.002
Adjusted OPG (2rd tertile vs. 1st) 2.50 1.08-5.78 0.032
Adjusted OPG (3rd tertile vs. 1st) 2.62 1.12-6.11 0.0026
Odds ratios (ORs) were assessed by logistic regression in univariate and
multivariable analyses (adjusted for sex and age).
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Figure 1 Diagram showing medians (interquartile range) of
plasma osteoprogeterin in low vs. high-risk patients (p <
0.001) and patients with or with significant coronary artery
disease (CAD; abnormal MPI and/or stenosis on coronary
angiography, (p < 0.001). High risk patients = patients with
plasma NT-proBNP levels >45.2 ng/l and/or CCS ≥400, all other low
risk patients.
Table 3 The relations between plasma OPG and the
prevalence of significant CAD as defined by abnormal
MPI and/or stenosis on CAG
Parameter OR 95% CI p-value
Study population as a whole (n = 200) ’Significant CAD’
Unadjusted OPG (2rd tertile vs. 1st) 2.74 1.23-6.10 0.013
Unadjusted OPG (3rd tertile vs. 1st) 4.24 1.93-9.31 0.0001
Adjusted OPG (2rd tertile vs. 1st) 3.51 1.39-8.86 0.008
Adjusted OPG (3rd tertile vs. 1st) 3.54 1.36-9.21 0.010
Odds ratios (ORs) were assessed by logistic regression in univariate and
multivariable analyses.
Covariate adjustments included variables associated with significant CAD in
univariate analysis (p < 0.05), including P-total cholesterol, P-creatinine,
peripheral systolic blood pressure, vibratory perception threshold and heart
rate variability.
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patients with P-OPG in the highest (third) vs. first tertile,
unadjusted and adjusted ORs of coronary artery stenosis
were 7.56 (1.64-34.99) and 14.20 (1.35-148.92), respec-
tively. Furthermore, among patients where CAG was per-
formed (n = 86), 91% of the patients with P-OPG in the
lower tertile (n = 22) had no >70% coronary artery stenosis
(p = 0.030). However, in the study population as a whole
the positive predictive value of high P-OPG for coronary
artery stenosis was only 19%.
Discussion
Principal findings
The present study of 200 type 2 diabetic patients with
microalbuminuria showed an independent predictive
value of P-OPG for significant CAD, and although P-
OPG correlated with P-NT-proBNP and CCS, its asso-
ciation with CAD remained significant after adjustment
for these risk markers. Among patients with significant
CAD (n = 70), 23 had >70% coronary artery stenosis at
CAG and P-OPG was also independently associated
with coronary artery stenosis. Among patients where
CAG was performed, 91% of patients with low P-OPG
did not have coronary artery stenosis at CAG.
P-OPG as a biomarker for subclinical CAD
Several studies have demonstrated that P-OPG is a
strong prognostic cardiovascular risk marker in diabetic
and non-diabetic populations [2-5]. For example, we
have found that in 283 type 2 diabetic subjects followed
for 17 years, high P-OPG predicted all-cause and cardio-
vascular mortality, independently of known CVD risk
markers including levels of albuminuria and P-NT-
proBNP[2]. The latter study was not designed to exam-
ine mechanisms behind the increased P-OPG and cardi-
ovascular death. In the current cross-sectional study, we
demonstrated that P-OPG was a risk marker for the
presence of subclinical CAD, which again may contri-
bute to the association with CVD mortality. OPG
expression is increased in the atherosclerotic arterial
wall and P-OPG has been suggested to reflect the arter-
ial OPG content and therefore be a surrogate marker of
arterial damage[8]. Along this line, OPG is up-regulated
in calcified coronary plaques[20] and P-OPG has been
associated with angiographic disease severity, indepen-
dent of conventional risk factors in other high risk
populations[9,10]. One considerably smaller study (n =
40) has previously found that P-OPG was a risk marker
for asymptomatic coronary artery stenosis in diabetic
patients with at least one additional conventional risk
factor[21]. In the present study, we confirm and extend
this observation in a larger and well-defined high risk
type 2 diabetic patient group with microalbuminuria.
Specifically, the demonstrated association of P-OPG
with CAD independent of NT-proBNP or CCS is new
and this finding adds significantly to the current knowl-
edge that P-OPG may be considered as an additional
marker of atherosclerosis.
Several studies have demonstrated that micro- and
macroalbuminura identifies a subgroup of diabetic
patients with increased morbidity and mortality from
CVD, but a recent study suggested that in the detection
of subclinical disease additional markers are in need[22].
Both NT-proBNP levels and CCS are established mar-
kers of CVD mortality with high independent predictive
capabilities in numerous populations[23,24]. Note-
worthy, NT-proBNP levels and CCS in combination
have synergistically predictive effect for CVD events in
asymptomatic patients without history or signs of CAD
followed for 3.9 years[25]. In contrast, other CVD mar-
kers fail to add prognostic value when compared with
NT-proBNP and CCS, respectively[26,27]. It is therefore
interesting in the present study, that P-OPG was inde-
pendent of NT-proBNP and CCS and this adds to the
body of evidence indicating that measurements of P-
OPG might be useful as a biomarker for CAD. ROC
analyses, however, revealed that the predictive accuracy
of OPG alone was low and OPG only slightly improved
the covariate model with NT-proBNP and CCS. Of
note, the combined model with NT-proBNP and CCS
without P-OPG already had an AUC of 0.84 and it is
therefore difficult to increase the area further. Along
this line, another study reported that P-OPG measure-
ments alone are insufficient as markers of endothelial
dysfunction[28]. Our study suggests that P-OPG could
be used in combination with other markers. Previous
studies that have used a multi biomarker approach have
not included bone metabolism and P-OPG. Bone meta-
bolism with P-OPG measurements may prove important
markers of vascular calcification. Actually, CCS and P-
OPG in combination could be particular interesting as
markers of structural and functional vascular calcifica-
tion, respectively. In the present study, P-OPG and CCS
were related and 80% of patients with low P-OPG (<1st
tertile) also had CCS < 400. Furthermore, in patients
with low P-OPG and/or CCS < 400, 83% of patients
were also without CAD, however the positive predictive
value was low (data not shown). Future studies may
show that OPG in combination with CCS, NT-proBNP
or other specific plasma markers may provide a strategy
to identify patients with subclinical CAD.
If OPG is also a mediator of CVD is not known but
OPG may influence plaque morphology and vulnerabil-
ity through the increased expression of matrix metallo-
proteinases[29] Knowledge, however, concerning
treatment effects on P-OPG and their possible link to
clinical outcome is sparse. An earlier study has showed
that low-dose simvastatin treatment for 18 weeks
reduced P-OPG in type 2 diabetic patients with
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microalbuminuria and mild hypercholesterolemia[30].
Also, a recent study reported that 6 months of pioglita-
zone decreased P-OPG levels in type 2 diabetic patients
[31]. However, in order to examine an effect on clinical
outcomes, substantially longer study periods are of
course needed, and a possible therapeutic benefit from
lowering P-OPG remains to be shown in larger inter-
vention studies.
Clinical implications
Although it has important prognostic impact to demon-
strate subclinical CAD, the therapeutic consequences of
diagnosing asymptomatic CAD in diabetic patients
remains to be shown. No randomized control trials have
as yet examined if myocardial revascularization is bene-
ficial in these asymptomatic patients, but in sympto-
matic diabetic patients receiving optimal medical
therapy there was no difference between the groups
receiving revascularization compared to controls[32].
Accordingly, the recommended primary and secondary
CAD treatment remains implementation of intensified
medical therapy aimed at reducing the conventional risk
factors. The diagnosis of subclinical CAD is likely to
encourage the efforts of both the patient and his/her
physician to reduce conventional risk factors more effec-
tively, which can diminish CVD morbidity as well as
mortality in these patients[12].
Limitations
As mentioned above, low (first tertile values) P-OPG
excluded the presence of >70% coronary artery stenosis
in 91% of the patients where CAG was performed
according to our risk stratification algorithm. Although
this was a high negative predictive value, there is
obviously a significant selection bias in play between
patients who had a CAG performed in the present study
compared to an unselected group of patients with type
2 diabetes and microalbuminuria Furthermore, the posi-
tive predictive value of P-OPG for coronary artery ste-
nosis was low. Therefore, the potential use of P-OPG as
a rule-out marker needs confirmation in a larger, pro-
spective study.
It is also notable, that we did not examine our 67 low
risk patients for significant CAD, since low P-NT-
proBNP and/or low CCS is associated with a very good
prognosis in these patients[13]. In this study we there-
fore assumed in most of our analyses that these 67
patients were without significant CAD. We found, how-
ever, that P-OPG was predictive of CAD within the high
risk group alone where all patients were investigated for
CAD. Other study limitations included the relatively
small sample size and that patients with elevated P-crea-
tinine were excluded to allow for examinations with CT
and CAG contrast media. Furthermore, all our patients
with microalbuminuria were aggressively medically trea-
ted, i.e., the value of P-OPG in the diagnosis of asymp-
tomatic CAD in less well-treated patients require
further studies.
Conclusion
Elevated P-OPG is an independent predictor of the pre-
sence of asymptomatic CAD in type 2 diabetic patients
with microalbuminuria. The effect of P-OPG was inde-
pendent of conventional CVD risk factors, including P-
NT-proBNP and CCS. P-OPG may represent a simple
test for excluding patients at high risk of subclinical
CAD.
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